<a href="https://laohu8.com/S/AMPH">Amphastar Pharmaceuticals</a> to Quadruple U.S. Manufacturing Capacity at Rancho Cucamonga Headquarters
Amphastar Pharmaceuticals Inc. has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga headquarters. The bio-pharmaceutical company, known for its complex generic and proprietary injectable, inhalation, and intranasal products, plans to quadruple its production capacity over the next three to five years. This strategic initiative marks the largest investment in domestic infrastructure in Amphastar's history and aims to enhance supply chain resilience. The expansion will include a state-of-the-art production plant and advanced technologies, creating new jobs in research and development, engineering, manufacturing, and quality operations. Amphastar's commitment to domestic manufacturing is underscored by its focus on producing essential medicines in the United States.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amphastar Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1048521) on July 14, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。